[go: up one dir, main page]

PE20070823A1 - Sal tosilato de 8-(2,6-difluorofenil)-4-(4-fluoro-2-metilfenil)-2-{[2-hidroxi-1-(hidroximetil)etil]amino}pirido[2,3-]pirimidin-7(8h)-ona - Google Patents

Sal tosilato de 8-(2,6-difluorofenil)-4-(4-fluoro-2-metilfenil)-2-{[2-hidroxi-1-(hidroximetil)etil]amino}pirido[2,3-]pirimidin-7(8h)-ona

Info

Publication number
PE20070823A1
PE20070823A1 PE2006001434A PE2006001434A PE20070823A1 PE 20070823 A1 PE20070823 A1 PE 20070823A1 PE 2006001434 A PE2006001434 A PE 2006001434A PE 2006001434 A PE2006001434 A PE 2006001434A PE 20070823 A1 PE20070823 A1 PE 20070823A1
Authority
PE
Peru
Prior art keywords
salt
weight
pyrimidin
hydroximethyl
pyrid
Prior art date
Application number
PE2006001434A
Other languages
English (en)
Inventor
As Ad Abu Khalil
Philip Blatcher
Lesley Anne Humphries
Jiri Kasparec
Richard Lloyd
Paul G Spoors
Lois E Vernon
John Robert George Appleby
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38049392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070823(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20070823A1 publication Critical patent/PE20070823A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UNA SAL TOSILATO DE 8-(2,6-DIFLUOROFENIL)-4-(4-FLUORO-2-METILFENIL)-2-{[2-HIDROXI-1-(HIDROXIMETIL)ETIL]AMINO}PIRIDO[2,3-d]PIRIMIDIN-7(8H)-ONA Y DERIVADOS EN UNA CANTIDAD DE 2,5-25%; B) 10-70% EN PESO DE POLIMERO RETARDADOR DE LA LIBERACION SELECCIONADO ENTRE HIDROXIPROPIL-CELULOSA, CARBOXIMETILAMIDA, CARBOXIMETILCELULOSA SODICA ENTRECRUZADA, ENTRE OTROS; C) 0-70% EN PESO DE DILUYENTE SELECCIONADO ENTRE LACTOSA, MANITOL, SORBITOL, SACAROSA, ALMIDON DE MAIZ MODIFICADO, ENTRE OTROS; D) 0-20% EN PESO DE ADYUVANTE DE COMPRESION SELECCIONADO ENTRE CELULOSA MICROCRISTALINA Y FOSFATO CALCICO; E) 0,1-2,5% EN PESO DE LUBRICANTE. REFERIDA TAMBIEN A DERIVADOS INTERMEDIARIOS ACIDO 6-CARBOXILICO DE PIRIDO[2,3-d]PIRIMIDIN-7-ONAS. LA FORMULACION, DE LIBERACION MANTENIDA, ES UTIL EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE, ENFERMEDAD INFLAMATORIA DEL INTESTINO, DOLOR NEUROPATICO, ATEROSCLEROSIS, ENTRE OTROS
PE2006001434A 2005-11-15 2006-11-13 Sal tosilato de 8-(2,6-difluorofenil)-4-(4-fluoro-2-metilfenil)-2-{[2-hidroxi-1-(hidroximetil)etil]amino}pirido[2,3-]pirimidin-7(8h)-ona PE20070823A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73667905P 2005-11-15 2005-11-15

Publications (1)

Publication Number Publication Date
PE20070823A1 true PE20070823A1 (es) 2007-08-09

Family

ID=38049392

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2010000447A PE20100743A1 (es) 2005-11-15 2006-11-13 Nuevos procedimientos y formulaciones
PE2006001434A PE20070823A1 (es) 2005-11-15 2006-11-13 Sal tosilato de 8-(2,6-difluorofenil)-4-(4-fluoro-2-metilfenil)-2-{[2-hidroxi-1-(hidroximetil)etil]amino}pirido[2,3-]pirimidin-7(8h)-ona
PE2010000446A PE20100742A1 (es) 2005-11-15 2006-11-13 Nuevos procedimientos y formulaciones

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2010000447A PE20100743A1 (es) 2005-11-15 2006-11-13 Nuevos procedimientos y formulaciones

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2010000446A PE20100742A1 (es) 2005-11-15 2006-11-13 Nuevos procedimientos y formulaciones

Country Status (18)

Country Link
US (1) US20080268044A1 (es)
EP (1) EP1954282A4 (es)
JP (1) JP2009516000A (es)
KR (1) KR20080074178A (es)
CN (3) CN101360497A (es)
AR (1) AR056218A1 (es)
AU (1) AU2006315162A1 (es)
BR (1) BRPI0618581A2 (es)
CA (1) CA2629912A1 (es)
CR (1) CR9992A (es)
EA (1) EA200801327A1 (es)
IL (1) IL191482A0 (es)
MA (1) MA29949B1 (es)
NO (1) NO20082541L (es)
PE (3) PE20100743A1 (es)
TW (1) TW200738243A (es)
WO (1) WO2007059500A2 (es)
ZA (1) ZA200803987B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059083A2 (en) 2000-10-23 2002-08-01 Smithkline Beecham Corporation Novel compounds
GB0308201D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
PE20100737A1 (es) * 2005-03-25 2010-11-27 Glaxo Group Ltd Nuevos compuestos
US20090318424A1 (en) * 2006-06-16 2009-12-24 Mauro Corsi Novel compounds
SI2068889T1 (sl) 2006-08-10 2020-03-31 Roy C. Levitt Anakinra za uporabo pri zdravljenju sindroma bronchiolitisa obliteransa
EP2481398A4 (en) * 2009-09-23 2013-03-06 Korea United Pharm Inc RETARD CILOSTA TOLL VEHICLE WITH IMPROVED ELUTION RATE AND MINIMAL SIDE EFFECTS
WO2012045072A2 (en) * 2010-10-01 2012-04-05 Mary Kay Inc. Sugar-based dispersion
ME03566B (me) 2013-03-14 2020-07-20 Amgen Inc So omekamtiv mekarbila i proces za pripremanje soli
EP3623371A1 (en) 2014-12-16 2020-03-18 Axovant Sciences GmbH Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
MX2017016231A (es) 2015-06-10 2018-11-29 Axovant Sciences Gmbh Compuestos de aminobencisoxazol como agonistas de receptores a7-nicotínicos de acetilcolina.
HK1253295A1 (zh) 2015-08-12 2019-06-14 Axovant Sciences Gmbh 作为7-烟碱乙酰胆碱受体的激动剂的偕取代的氨基苯并异恶唑化合物
EP3691620B1 (en) 2017-10-05 2022-07-27 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
JP6983139B2 (ja) * 2017-11-27 2021-12-17 信越化学工業株式会社 固形製剤用組成物並びに固形製剤及びその製造方法
US10980747B2 (en) * 2017-11-27 2021-04-20 Shin-Etsu Chemical Co., Ltd. Composition for solid preparation, solid preparation, and method for producing the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ322197A (en) * 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
US6875769B2 (en) * 1996-05-23 2005-04-05 Pfizer Inc. Substituted6,6-hetero-bicyclicderivatives
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
ZA99733B (en) * 1998-01-30 1999-08-02 R Tech Ueno Ltd Ophthalmic composition.
WO2002059083A2 (en) * 2000-10-23 2002-08-01 Smithkline Beecham Corporation Novel compounds
CA2431904A1 (en) * 2000-12-20 2002-08-01 Merck & Co., Inc. (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents
WO2003026662A1 (en) * 2001-09-25 2003-04-03 Pharmacia Corporation Solid-state forms of n-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl)pyrazole

Also Published As

Publication number Publication date
AR056218A1 (es) 2007-09-26
CN101360497A (zh) 2009-02-04
EA200801327A1 (ru) 2009-02-27
NO20082541L (no) 2008-08-14
PE20100742A1 (es) 2010-11-25
JP2009516000A (ja) 2009-04-16
AU2006315162A1 (en) 2007-05-24
IL191482A0 (en) 2009-02-11
BRPI0618581A2 (pt) 2011-09-06
WO2007059500A3 (en) 2007-11-22
CR9992A (es) 2008-07-29
MA29949B1 (fr) 2008-11-03
CA2629912A1 (en) 2007-05-24
WO2007059500A2 (en) 2007-05-24
EP1954282A2 (en) 2008-08-13
ZA200803987B (en) 2009-12-30
CN102030748A (zh) 2011-04-27
CN102030749A (zh) 2011-04-27
KR20080074178A (ko) 2008-08-12
US20080268044A1 (en) 2008-10-30
TW200738243A (en) 2007-10-16
PE20100743A1 (es) 2010-11-25
EP1954282A4 (en) 2011-10-12

Similar Documents

Publication Publication Date Title
PE20070823A1 (es) Sal tosilato de 8-(2,6-difluorofenil)-4-(4-fluoro-2-metilfenil)-2-{[2-hidroxi-1-(hidroximetil)etil]amino}pirido[2,3-]pirimidin-7(8h)-ona
KR101483834B1 (ko) 항바이러스 화합물
CL2011000353A1 (es) Compuestos derivados de 1-{4-[metil(7h-pirrolo[2,3-d]pirimidin-4-il)amino]ciclohexil}metanosulfonamida o una sal farmaceuticamente aceptable; forma cristalina de la sal maleato; procedimiento de preparacion; composicion farmaceutica; y uso para tratar enfermedades alergicas, cancer, lupus.
ES2587533T3 (es) Derivados de purina y su uso en el tratamiento de enfermedades
CA2946408C (en) Compounds and compositions as toll-like receptor 7 agonists
JP5902704B2 (ja) Ｈｉｖ複製の阻害剤
EP4093385A1 (en) Pgdh inhibitors and methods of making and using
AU2020201114A1 (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
JP4248239B2 (ja) プリン作用性レセプターアンタゴニストとしてのピロロ［２，３−ｄ］ピリミジンおよびそれらの使用
EP4424315A2 (en) Novel compounds
HRP20180202T1 (hr) Purinski derivati, namijenjeni upotrebi u liječenju alergijskih, upalnih i zaraznih bolesti
JP2025168374A (ja) アロステリックｅｇｆｒ阻害剤及びその使用方法
RS51885B (sr) PIRIDIN[3,4-b] PIRAZINONI
GT200000170A (es) Agentes terapeuticos.
WO2010098839A1 (en) Pde 1 inhibitors for ophthalmic disorders
EP2400962A1 (de) Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids
CA2931758A1 (en) Fused tricyclic imidazole derivatives as modulators of tnf activity
EP2081431A1 (en) Organic compounds
JPWO2001080893A1 (ja) 排便を促進する医薬組成物
CN116462679A (zh) 一种吡唑并嘧啶衍生物及其在医药上的应用
KR20150084022A (ko) 폐동맥 고혈압 및 폐 손상의 치료에 이용하기 위한 1,3-디히드로이미다졸-2-티온 유도체
RU2008118995A (ru) Антагонист аденозинового рецептора а2а для изготовления лекарственного средства для лечения фибрилляции предсердий
CN114656429A (zh) 一类抗炎镇痛化合物及其用途
PE20090978A1 (es) DERIVADOS DE FURO {3,2-d} PIRIMIDINA
HK40070401A (en) Compounds of anti-inflammatory and analgesic and applications thereof

Legal Events

Date Code Title Description
FC Refusal